Registry of Lobbyists
Total Number of Communication Reports: 8
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Health, Research and Development
|
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
|
Legislative Proposal, Bill or Resolution
|
|
Economic Development, Health, Industry, Research and Development, Science and Technology
|
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
|
Regulation, Policies or Program
|
|
Budget, Health
|
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
|
Health, Research and Development
|
Implementation of Canada's action plan for pain and federal initiatives related to pain management.
|
Policies or Program
|
|
Health, Research and Development
|
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
|
Policies or Program, Legislative Proposal, Bill or Resolution
|
|
Economic Development, Health, Industry, Intellectual Property, Research and Development, Science and Technology
|
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
|
Policies or Program
|
|
Health, Industry, Intellectual Property
|
Regulations, guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
|
Policies or Program, Regulation
|
|
Health, Intellectual Property, Research and Development
|
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
|
Regulation
|
Address:
20 Bay Street
Suite 1520
Toronto, ON M5J 2N8
Canada
Telephone number:
647-790-1602
Web address:
www.vrtx.com
Prabh Grewal, Senior Manager, Public Affairs
Vertex Pharmaceuticals (Canada) Inc. is not a coalition.
The activities of Vertex Pharmaceuticals (Canada) Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Vertex Pharmaceuticals (Canada) Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
WILLIAM DEMPSTER | Public offices held
Firm: 3Sixty Public Affairs Inc. / 3Sixty Public Affairs Inc.